Cell transplantation for diabetes
Cell transplantation for diabetes
复制标题
DOI：
10.1098/rstb.2005.1707
复制
发表时间：
2005-09-29
影响因子：
6.3
通讯作者：
Calne, R
中科院分区：
文献类型：
--
作者：
Calne, R
30年来，人们一直在进行胰岛移植治疗糖尿病的实验工作，以期治愈疾病并预防继发并发症。经历了许多技术困难，首先是在不损坏胰岛的情况下分离胰岛，其次是找到合适的注射位置，但直到最近，血管化胰腺移植的结果一直优于胰岛移植。 2000年，由夏皮罗领导的埃德蒙顿研究小组发表了令人鼓舞的结果，该研究小组在患者病程早期使用不同的免疫抑制药物进行移植，这一结果与之前的尝试不同。对于 I 型糖尿病患者来说，一年后的结果非常好，两年后的结果也很好，但五年后的结果却令人担忧。尽管如此，埃德蒙顿的观察结果证明了概念，并增强了人们对治疗糖尿病和其他疾病的兴趣，这些疾病需要细胞移植和/或基因工程合成特定的蛋白质。最近对胚胎干细胞的兴趣减轻了这些努力，并且在确定困难方面正在取得进展，这比大多数工作人员预期的要大。在这篇综述中，讨论了该主题，解释了需要在哪些方面取得进展，以便为患者提供有价值的治疗。
For 30 years there has been experimental work aimed at transplanting islets for the treatment of diabetes with a view to curing the disease and preventing the secondary complications. Many technical difficulties were experienced, first in isolating the islets without damaging them, and second in finding a suitable place to inject them, but until recently the results of a vascularized pancreas transplant have been superior to islet transplantation. In 2000, the group in Edmonton, headed by Shapiro, published encouraging results using a different immunosuppression in transplanting patients earlier in the course of their disease than had been attempted previously. The results were excellent at a year and good at 2 years in patients with Type I diabetes, however there was the rather worrying attrition at five years. Nevertheless, the Edmonton observations were proof of concept and have intensified interest in treating diabetes and other diseases where a specific protein synthesis was required by cell transplantation and/or genetic engineering. The recent interest in embryonic stem cells extenuated these efforts and progress is being made in defining the difficulties, which are greater than most workers would have predicted.In this review, the subject is discussed explaining where progress needs to be made in order to provide treatment that would be of value to patients.